Thrombophilia Tests in the package: 5 Sample: blood Result: 7 working days

Profile of genetic risk factors for thrombophilia: mutations - factor V Leiden (G1691A), factor II (prothrombin G20210A), MTHFR (C677T, A1298C), factor XIII (V34L), detection of the PAI-1 4G/5G polymorphism (RT-PCR)

Genetic testing by RT-PCR for five inherited risk factors for thrombosis: factor V Leiden, prothrombin (factor II) G20210A, MTHFR C677T and A1298C, factor XIII V34L and PAI-1 4G/5G. The result helps to assess the risk of thrombosis after a previous clot, in pregnancy, with hormone therapy and before surgery.

Package code CS00856 Preparing for laboratory tests

Some laboratory tests require specific preparation by the patient, concerning diet before sampling and the time of day at which to come to the laboratory for sampling. The patient can be informed about this by their doctor or by the staff of Sante Laboratorije. Many other tests, however, need no prior preparation, and samples do not have to be collected at a particular time or in relation to meals.

For information, contact us on +381 11 27 62 199 | +381 64 65 87 607 or in writing at office@clinica-sante.rs.

Profile of genetic risk factors for thrombophilia: mutations - factor V Leiden (G1691A), factor II (prothrombin G20210A), MTHFR (C677T, A1298C), factor XIII (V34L), detection of the PAI-1 4G/5G polymorphism (RT-PCR)

Preparation and sampling

Preparation
Guide to preparing for tests
Sample
Blood
Results available in
7 working days
Where it is done
All laboratories and map

Description

Who the package is for

This genetic test detects inherited (germline) gene variants that affect blood clotting and are linked to a tendency to venous thrombosis, that is, deep vein thrombosis and pulmonary embolism. In certain situations, particularly together with other risk factors (immobility, surgery, pregnancy and the period after childbirth, oestrogen-containing contraception, obesity, cancer), these variants can also contribute to pregnancy complications such as recurrent pregnancy loss, growth restriction of the baby and pre-eclampsia. The test is recommended, as advised by a doctor:

  • for people who have had a deep vein thrombosis or pulmonary embolism, particularly before the age of 50 or without a clear cause;
  • for recurrent thrombosis or thrombosis in unusual sites (veins of the brain, bowel or liver);
  • for women with recurrent pregnancy complications, and when planning a pregnancy or assisted reproduction;
  • before oestrogen hormone therapy or cancer treatment, after assessment by a doctor;
  • for first-degree relatives of people with a confirmed factor V Leiden or prothrombin mutation.

What the package includes

  • Factor V Leiden (G1691A) mutation – a point mutation that makes factor V resistant to breakdown by activated protein C (activated protein C resistance); the most common inherited risk factor for venous thrombosis.
  • Prothrombin (factor II) G20210A mutation – a point mutation that increases the production of prothrombin and therefore the tendency to clot.
  • MTHFR variants (C677T, A1298C) – polymorphisms of the gene for an enzyme of folate metabolism; they can contribute to raised homocysteine, and their significance is judged in the clinical context.
  • Factor XIII variant – the V34L polymorphism of the factor XIII gene, with a variable effect on the stabilisation of the fibrin clot.
  • PAI-1 gene variant (4G/5G) – a variant in the regulatory region (promoter) of the gene for plasminogen activator inhibitor 1, which can change its activity and slow the breakdown of clots; a susceptibility marker.

Why these tests together

The variants of the five genes tested act on different parts of the clotting and clot-dissolving system, so together they give a broader picture of the genetic tendency:

  • factor V Leiden and prothrombin G20210A are the variants with the best-established effect on the risk of venous thrombosis, and carrying both at once increases the risk further;
  • MTHFR affects folate and homocysteine metabolism, PAI-1 the breakdown of clots and factor XIII the stability of the clot; these are susceptibility markers with a smaller and variable individual effect;
  • all variants are determined from the same DNA sample by RT-PCR (real-time polymerase chain reaction) with specific probes, with positive and negative controls and an internal amplification control.

The result helps to assess the risk of venous thrombosis and to decide on protection against thrombosis in high-risk situations (surgery, pregnancy, immobility), on hormonal contraception and oestrogen therapy, and on genetic counselling of the family when factor V or prothrombin variants are found.

Preparation

  • No special preparation is needed: the genetic result does not depend on diet, the time of day or treatment, so you do not need to fast, and you should not stop any medicines, including anticoagulants.
  • The test is done once in a lifetime, because inherited genes do not change.
  • If you have had a bone marrow transplant or a recent blood transfusion, say so before sampling.
  • If you have one, bring your doctor's referral, as well as information on previous thromboses in you or your family and on any pregnancy complications, as they matter for interpretation.

Sample

Venous blood collected into an EDTA tube, from which DNA is extracted.

Interpreting the results

  • For each variant, the result is reported as a genotype: no change (so-called wild type), heterozygous (a change in one copy of the gene) or homozygous (a change in both copies), with a note on the technical limitations.
  • Factor V Leiden and prothrombin G20210A – in heterozygous carriers the risk of venous thrombosis is moderately increased, and in homozygous carriers or with both variants together it is considerably higher.
  • MTHFR, PAI-1 and factor XIII – these variants are also common in the general population and, without other risk factors, have limited significance; they are interpreted with caution, and with an MTHFR result it is useful to measure homocysteine.
  • The genetic result does not replace clinical assessment: the overall risk of thrombosis depends on the interaction between inherited variants and acquired factors.
  • The test does not cover other causes of thrombophilia, such as protein C, protein S or antithrombin deficiency and antiphospholipid syndrome, so further tests may be needed. RT-PCR detects only the listed variants, not other rare mutations.

Your doctor interprets the result together with your symptoms and other findings.

Tests in the package

Single-test prices are online prices: 19.805 RSD separately, 19.800 RSD in the package.

How to order tests online?

Add the tests you want to your cart

Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.

Pay online or at the laboratory

Payment method:

  • Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
  • At the laboratory – order your tests online and pay for them when you come to the laboratory.
Have your samples taken at one of our laboratories

After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.

Learn more
Back to top